Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.
Taliya Lantsman, MD
Advertisement
Taliya Lantsman, MD, is a hematology/oncology fellow at Beth Israel Deaconess Medical Center.
Articles by Taliya Lantsman, MD
Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.
Advertisement
Latest Updated Articles
Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial CancerPublished: March 18th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5